|
TBCCD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63846713974181E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.67400546150043E-11 |
| Normal-vs-Stage2 |
1.03720000033114E-07 |
| Normal-vs-Stage3 |
3.64153152077051E-14 |
| Normal-vs-Stage4 |
1.72328817882317E-12 |
| Stage1-vs-Stage2 |
6.840800E-01 |
| Stage1-vs-Stage3 |
6.635800E-03 |
| Stage1-vs-Stage4 |
4.077200E-03 |
| Stage2-vs-Stage3 |
1.488570E-01 |
| Stage2-vs-Stage4 |
5.041700E-02 |
| Stage3-vs-Stage4 |
4.641600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.36397576461422E-14 |
| Normal-vs-AfricanAmerican |
4.02520000000184E-05 |
| Normal-vs-Asian |
4.49889999698527E-08 |
| Caucasian-vs-AfricanAmerican |
6.372200E-01 |
| Caucasian-vs-Asian |
8.124600E-01 |
| AfricanAmerican-vs-Asian |
8.080800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.04725125740879E-13 |
| Normal-vs-Female |
2.06068495600675E-12 |
| Male-vs-Female |
2.975800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.88520018776728E-10 |
| Normal-vs-Age(41-60Yrs) |
3.76254583045466E-13 |
| Normal-vs-Age(61-80Yrs) |
1.67887925783816E-12 |
| Normal-vs-Age(81-100Yrs) |
7.405400E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.882000E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.028000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.998000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.550000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.983000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.680600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.988900E-04 |
| Classical-VS-Follicular |
2.825600E-01 |
| Classical-VS-Other |
3.775800E-01 |
| Classical-VS-Normal |
1.28369537222284E-11 |
| Tall-VS-Follicular |
2.217700E-02 |
| Tall-VS-Other |
6.607400E-01 |
| Tall-VS-Normal |
4.54525306281539E-13 |
| Follicular-VS-Other |
6.361200E-01 |
| Follicular-VS-Normal |
8.08930034068567E-10 |
| Other-VS-Normal |
9.620700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.30147020832783E-12 |
| Normal-vs-N1 |
2.64190003207432E-10 |
| N0-vs-N1 |
2.092800E-01 |
|
|
